Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Formoterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 11/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 5/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 4/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arformoterol SCHEMBL30154976 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL3679114 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL30969874 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL6547706 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Formoterol SCHEMBL6528975 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL458736 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Formoterol SCHEMBL349579 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL117865 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL4247 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL29640690 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125397-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4711005-A2 | METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH | Stealth BioTherapeutics Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12576051-B2 | Methods and composition for treating respiratory obstructive diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260061023-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROME | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260062752-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND DIAGNOSING DISEASES AND CONDITIONS | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2026041740-A1 | TREATMENT OF HIGH-RISK ASTHMA BY BLOCKING IL-13 AND TSLP | SANOFI (FR) | 2026-02-26 | — | — | WO | disclosed |
| EP-4680604-A2 | METHOD OF TREATING ENTEROVIRUS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS | Altesa Biosciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4190321-B1 | MICROPARTICLES WITH GOLF BALL DEPRESSIONS FOR USE IN THE TREATMENT AND PREVENTION OF DISEASES PER INHALATION | AQUILON PHARMACEUTICALS (BE) | 2026-01-21 | — | — | EP | disclosed |
| EP-4397314-B1 | TREATMENT OF LEFT VENTRICULAR REMODELING | STEALTH BIOTHERAPEUTICS INC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12453727-B2 | Montelukast salts and pharmaceutical compositions containing the same | GENETIC S.P.A. (IT) | 2025-10-28 | — | — | US | disclosed |
| EP-3986899-A1 | PYRAZOLOPYRIMIDINE ARYL ETHER INHIBITORS OF JAK KINASES AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| US-11312993-B2 | Methods and compositions for detecting and diagnosing diseases and conditions | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-04-26 | — | — | US | disclosed |
| WO-2022074183-A1 | A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-04-14 | — | — | WO | disclosed |
| CN-107750177-B | Use of antistatic materials in airways for hot aerosol condensation processes | 艾利斯达医药品公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3963055-A1 | VECTORIZED ANTIBODIES (VAB) AND USES THEREOF | Voyager Therapeutics, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| US-20170081276-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2017-03-23 | — | — | US | disclosed |
| US-9522871-B2 | Preparation of (R,R)-fenoterol and (R,R)-or (R,S)-fenoterol analogues and their use in treating congestive heart failure | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-12-20 | — | — | US | disclosed |
| EP-2064174-B1 | PREPARATION OF (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | US GOV HEALTH & HUMAN SERV (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160009636-A9 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-01-14 | — | — | US | disclosed |
| US-20140187645-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009636-A9 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885ADRB1 2/4885ADRB3 3/4885 |
| US-20260061023-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROME | ARG2, ARGLU1, BCAT1 | ADRB2 2718/4885ADRB1 3034/4885ADRB3 2070/4885 |
| US-20170081276-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885ADRB1 2/4885ADRB3 3/4885 |
| US-12453727-B2 | Montelukast salts and pharmaceutical compositions containing the same | ADRB2, CYSLTR2, LTB4R2 | ADRB2 1/4885ADRB1 4/4885ADRB3 6/4885 |
| US-20260125397-A1 | MK2 DEGRADERS AND USES THEREOF | NR2C2, NR3C2, OXER1 | ADRB2 604/4885ADRB1 1610/4885ADRB3 2084/4885 |
| US-12576051-B2 | Methods and composition for treating respiratory obstructive diseases | CFTR, CCR10, SLC26A4 | ADRB2 126/4885ADRB1 114/4885ADRB3 36/4885 |
| US-20140187645-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885ADRB1 2/4885ADRB3 3/4885 |
| US-20260062752-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND DIAGNOSING DISEASES AND CONDITIONS | ARG2, MTPN, TNNT2 | ADRB2 3271/4885ADRB1 2503/4885ADRB3 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.